
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc is positioned favorably due to its substantial drug development progress targeting recurrent glioblastoma and leptomeningeal metastases, with significant milestones anticipated in 2025 and 2026. The company’s financial outlook is bolstered by an $18 million grant awarded by the Cancer Prevention and Research Institute of Texas, which will support its research efforts in treating leptomeningeal metastases. Additionally, a positive net present value (NPV) analysis reinforces the stock’s potential, indicating considerable upside based on current performance metrics.
Bears say
Plus Therapeutics Inc faces significant risks that contribute to a negative outlook, including the potential failure of its product candidates to demonstrate safety and efficacy in clinical trials, which could hinder regulatory approvals and commercial viability. Additionally, the company's pro forma earnings per share (EPS) of $0.02, while positive, is notably below prior estimates of $(0.13) and consensus expectations of $(0.12), indicating potential financial instability. Moreover, external factors such as competition and changing macroeconomic conditions further exacerbate the uncertainties surrounding the company's ability to sustain or grow its market position.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares